BMY: מכפיל מחיר להכנסות Bristol Myers Squibb Company

סמל ולוגו של המותג BMS (BMY)

Bristol-Myers Squibb (BMY) is aggressively acquiring small biotech startups to refresh its development pipeline. This chart on the GURU.Markets platform illustrates the price-to-sales ratio reflecting the market valuation of the business, while the 2.60 value shows the most recent figure. The holding's revenues are based on the sale of patented drugs for cancer and heart disease, however, geopolitical fractures and sanctions in research regions create serious operational risks.

bms.com - יחס מחיר להכנסות BMY (תקופה 04.07.2022 - 16.11.2026)

פילוחי מדדים ואנליטיקה של חברת bms.com (BMY)

אנליטיקה מסכמת של החברה:Bristol Myers Squibb Company
מוצר עיקרי של Bristol-Myers Squibb

The P/S ratio reflects the market value of a single unit of sales, allowing for the determination of an asset's overvaluation by comparing market capitalization with actual revenue. By analyzing the price-to-sales ratio changes on GURU.Markets, an investor can see how the market discounts the costs incurred by Bristol-Myers Squibb (BMY) to implement "green chemistry" and ESG standards, which impact the operational efficiency of this biopharmaceutical behemoth.